Anti-FLT3 (Phospho-Tyr969) antibody
Specifications
| Product Cat#: | AB-07-0516 |
| Product type: | Primary antibody |
| Antigen: | FLT3 (Phospho-Tyr969) |
| Immunogen: | A synthetic peptide derived from human FLT3 (Phospho-Tyr969) . The exact amino-acid sequence is proprietary. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot: 1:500~1:3000 Immunohistochemistry: 1:50~1:100 ELISA: 1:5000 |
| Reactivity: | Human |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | PBS (without Mg2+ and Ca2+ ), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Concentration: | 1 mg/ml |
| Purity: | Antigen affinity chromatography |
| Storage: | Aliquot and freeze at -20°C. Avoid multiple freeze/thaw cycles. |
| Alternative names: | FLT3 (Phospho-Tyr969);CD135; EC 2.7.10.1; fetal liver kinase 2; FL cytokine receptor; FLK-2; FLT-3; FLT3; fms-related tyrosine kinase 3; kinase Flt3; stem cell tyrosine kinase 1; STK-1; STK1 |
Target information
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.
Provider
Erpantech Laboratory
